Nuvation Bio (NUVB) started an expanded access program of taletrectinib in the US to treat certain patients with non-small cell lung cancer.
The program covers patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer without comparable or satisfactory treatment alternatives, the company said Monday in a statement.
Under the program, taletrectinib will be available to patients with serious or immediately life-threatening condition outside Nuvation's phase 2 Trust-II study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.